CABT-B12288

antibody from Creative Diagnostics

Targeting: CLEC4C BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL

Flow cytometry (Recommended by provider)

Antibody Data

Product number

CABT-B12288

Provider

Creative Diagnostics

Product name

Mouse anti-Human CLEC4C monoclonal antibody

Antibody type

Monoclonal

Description

CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission.7,11 Furthermore, CD303 (BDCA-2) antibodies were used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization8 or transplantation10 . CD303 (BDCA-2) antibodies were also used for immunohistochemical staining, for example to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases.5,12,13 It recognozes the the CD303 (BDCA-2) antigen1,3 which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow) and non-lymphoid tissue.3,6 Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker.1\u201311 CD303 (BDCA-2)+ plasmacytoid dendritic cells in blood and bone marrow are CD11c\u2013 , CD123high , CD4+ , Lin\u2013 , CD45RA+ , CD304 (BDCA-4/Neuropilin-1)+ , CD141 (BDCA-3)low , CD1c (BDCA-1)\u2013 , CD14\u2013 , and CD2\u2013 . They express neither myeloid lineage markers (CD13, CD33) nor Fc receptors (CD32, CD64, FcRI).1,6 CD303 (BDCA-2) is strongly expressed on freshly isolated plasmacytoid dendritic cells but down-regulated within 48 hours of culturing.1 Unlike CD304 (BDCA-4/Neuropilin-1), CD303 (BDCA-2) is not detectable on ex vivo generated monocyte-derived or hematopoietic precursor cell-derived CD1a+ dendritic cells.1,9 The CD303 (BDCA-2) antigen is a novel type II transmembrane C-type lectin.3 Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells.1,3 Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I IFN production, which is induced in plasmacytoid dendritic cells by, for example, the influenza virus.3,6

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 _g in 100 _L

Storage

Store protected from light at 2ÿ8 °C. Do not freeze.